The Global Spinal Fusion Devices Market size is expected to reach $9. 7 billion by 2028, rising at a market growth of 4. 6% CAGR during the forecast period. Spinal instrumentation also called spinal implants, devices, or hardware involves the implantation of titanium, stainless steel, titanium-alloy, or non-metallic items into the spine by surgical procedures.

New York, June 02, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Spinal Fusion Devices Market Size, Share & Industry Trends Analysis Report By Surgery, By Type, By End User, By Regional Outlook and Forecast, 2022 – 2028" - https://www.reportlinker.com/p06283468/?utm_source=GNW Spinal instrumentation is a long-term remedy for spinal instability. Medical implants come in a variety of forms, styles, and sizes, all of which are designed to treat spinal diseases in people of all age groups. Spinal fusion devices are used to treat spondylolisthesis and degenerative disc disease, as well as other spinal abnormalities. The rise in the elderly population along with the rise in the prevalence of spinal disorders is driving the market’s growth. Furthermore, the market is expected to rise as the number of indications for spinal fusion surgery grows. For example, spinal fusion was once reserved for spinal tuberculosis & scoliosis, but it is now used to treat 14 other disorders. In men & women over the age of 50, spine problems like spinal stenosis are the most common condition. The elderly, especially those with comorbidities and/or reduced immunity, are at a higher risk of spinal abnormalities. With the emergence of new-age spine fusion and gadgets, spine-level therapy choices are always increasing. In addition, the usage of these implants and devices is one of the most successful and well-recommended treatments for spine misalignments and degenerative alterations. The trend toward less invasive spine operations, the rise in the prevalence of spinal illnesses, and innovations in spine surgery are all major factors driving the growth of the spinal fusion devices market. Surgeons are choosing MIS over open surgery for a variety of reasons, including less pain, a shorter recovery time, and less tissue damage. Minimally invasive procedures are being used to treat a wide spectrum of bone problems. In the United States, around 400,000 spinal fusion procedures are performed each year, making it one of the most prevalent and well-established treatment choices for spine trauma, degenerative conditions, and structural anomalies. COVID-19 Impact COVID-19 has spread all over the world. In addition, because of a rise in the number of coronavirus patients, governments all over the world have implemented several regulations and lockdowns, resulting in the closure of manufacturing & production operations of companies in the spinal fusion devices industry. Moreover, as surgeons and Practitioners focus on treating corona patients, hospitals have announced reductions, postponement, or cancellations of elective procedures, including many orthopaedic and spine cases. This break in the flow of business operations and other relevant activities has a direct impact on the market. As a result, the above-mentioned factors are estimated to restrain the growth of the spinal fusion devices market. Market Growth Factors The Development of Robotic Spine Fusion Surgery Surgical robots are increasingly being used in the spine treatment industry, with several hospitals now giving robotic surgery for the treatment of numerous spinal injuries and disorders. Many companies are focusing on developing surgical robots that may be utilized in conjunction with their implants & navigation aids in spinal fusion surgery. This has majorly increased the number of strategic partnerships as well as new product launches, all of which are estimated to propel the market forward. Medtronic announced the launch of Mazor X Stealth Edition, a robotic system for spine surgery, in January 2019. The technology may be combined with the company’s navigation, spine implants, and 3D imaging capabilities to provide healthcare providers with a complete solution. Rising number of novel innovations across the spinal fusion market The market for spinal arthrodesis devices is fiercely competitive, with major competitors launching new and sophisticated products regularly to sustain their position in the market. Moreover, minimally invasive operations are gaining adoption around the world, prompting manufacturers to introduce devices designed specifically for minimally invasive spinal fusion surgery. Alphatec Spine, for instance, announced the commercial introduction of Invictus, a spine fixation platform created for open, minimally invasive, or hybrid surgical procedures, in July 2019. The increasing number of advancements and innovations in the spinal fusion devices would significantly boost demand for these devices. Market Restraining Factors Risk of Spinal discomfort & longer healing time due to bone grafting A fusion entails substantial bone grafting, which might result in increased back discomfort and an increased healing time. Throughout a fusion, the lateral facet joints & transverse processes, which are parts of pine that are placed on the sides of each vertebra, are usually exposed. More muscle dissection is required as a result. Bone grafts or bone substitutes are also used in the spine to aid in the gradual fusion of the bones, although this might cause inflammation, which can add to additional scarring, or arachnoiditis, and pain. Surgery Outlook Based on Surgery, the market is segmented into Minimally Invasive Spine Surgery and Open Spine Surgery. The Open Spine surgery garnered substantial revenue share in spinal fusion devices market in 2021. The growing desire for open spine procedures among medical professionals, the increasing incidence of spinal abnormalities, and technological breakthroughs in spinal fusion surgery all contribute to growth of this segment. Tele audiology can be a useful approach for persons who are experiencing hearing loss during this period to get the care that eliminates or limits conventional face-to-face engagement. Type Outlook Based on Type, the market is segmented into Thoracolumbar Devices, Cervical Fixation Devices, and Interbody Fusion Devices. The Cervical Fixation devices segment procured a significant revenue share in the spinal fusion devices market in 2021 because of rapid adoption of spine navigation software and attractive health insurance coverage. Cervical plates help fusion by keeping the construct stable. The novel cervical interbody device is comprised of titanium alloy and is cylindrical. The device collects bone material needed for fusion as it is inserted between two vertebrae. End User Outlook Based on End User, the market is segmented into Hospitals, Specialty Clinics, and Others. The Hospitals segment acquired the highest revenue share in spinal fusion devices market in 2021. Because of the increasing adoption of advanced spine surgery products along with the progressive growth in the number of robotic spine surgeries, in addition hospitals are witnessing significant cost savings from spinal fusion procedures, which is expected to boost the market even further. Regional Outlook Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America acquired the highest revenue share of the spinal fusion market in 2021. The regional market is likely to be fueled by a significant increase in the number of spinal fusion procedures performed in ambulatory surgical centers and outpatient settings, as well as the rapid use of spine navigation tools and surgical robots. Significant number of adults in the United States experienced chronic pain in 2016, with few among them experiencing high-impact chronic pain. During the projection period, this is likely to boost demand for spine fusion implants in the United States. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zimmer Biomet Holdings, Inc., Johnson & Johnson, Stryker Corporation, B. Braun Melsungen AG, Medtronic PLC, Alphatec Holdings Inc., Globus Medical, Inc., NuVasive, Inc., Orthofix Medical, Inc., and Exactech, Inc. Strategies deployed in Spinal Fusion Devices Market Feb-2022: Orthofix Medical introduced Opus BA for commercial use in the market. It is a synthetic bioactive bone graft solution for cervical & lumbar spine fusion procedures. It can be used to fill voids in the bone or skeletal system’s gap that is not inherent to the balance of bony structure. In addition, Opus BA mimics a scaffold permitting bone growth over the surface that is reabsorbed & substituted with natural bone during the healing process. Jan-2022: Exactech signed an agreement to acquire JointMedica, a U.K based orthopedic device designer & manufacturer. This collaboration aimed to give the coming generation of hip resurfacing to the global market with JointMedica, the Polymotion hip implant. Sep-2021: Alphatec Holdings introduced the InVictus OsseoScrew Expandable Spinal Fixation System. This system is created to be a substitute for the traditional use of cemented fenestrated screws for patients with compromised bone. The system is made with an intention to again store spinal column integrity, even in the absence of fusion, in patients with advanced-stage tumors involving the lumbar & thoracic spine in whom life expectancy is of not sufficient duration to allow achievement of fusion. Apr-2021: Globus Medical released the new product CREO ONE, the first robotic screw in the market created for spine surgery with ExcelsiusGPS. This new release would improve the company’s groundbreaking modular pedicle screw platform by making simple pedicle preparation while maintaining the precision of navigation & raising pullout strength by 86% in comparison with conventional pedicle screws tapped to size. Feb-2021: NuVasive completed the acquisition of Simplify Medical, a private company & developer of Simplify Cervical Artificial Disc (Simplify Disc) for cervical total disc replacement (cTDR). This acquisition aimed to distinguish NuVasive’s cervical portfolio and sums up the most clinically effective cTDR technology in the market. Nov-2020: Medtronic took over Medicrea, a french artificial intelligence company. Under this acquisition, Medicrea’s technology would be combined into the Spine of Medtronic division. This acquisition aimed to offer an integrated solution comprising artificial intelligence-driven personalized spinal implants, surgical planning, and robotic-assisted surgical delivery, which would give them control of these smart technologies straight into the hands of clinicians to make patient care more personalized & tailored. Sep-2019: DePuy Synthes, a Johnson & Johnson Medical Devices Companies introduced CONDUIT Interbody Platform with EIT Cellular Titanium Technology, which would widen its offering to treat degenerative spine disease. This innovative portfolio comprises 3D printed titanium interbody, which would carry out spinal fusion surgery to imitate natural bone & help facilitate spinal fusion. Aug-2019: NuVasive unveiled Modulus TLIF-A for commercial use. It is a porous titanium spine implant engineered for the transforaminal lumbar interbody fusion (TLIF) procedure. This offering completes the Company’s Advanced Materials Science (AMS) portfolio for all major posterior interbody fusion techniques used in TLIF, the most usually performed procedure in the spine industry. The availability of Modulus TLIF-A furthermore extends NuVasive’s technology contribution to the spinal deformity market given its differentiated ability to deliver anterior column support, raise segmental maximize the capability to restore sagittal alignment & lordosis. Jul-2019: Alphatec Holdings unveiled IdentiTi Large Window Porus Titanium Interbody Implant System for commercial use. This system is for anterior lumbar interbody fusion (ALIF) procedures, which is manufactured using a subtractive process that generates more predictable performance. Sep-2018: Johnsons & Johnsons, a subsidiary of Johnsons & Johnsons Medical Devices signed an agreement to acquire Emerging Implant Technologies GmbH (EIT), a privately-held manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery, located in Wurmlingen, Germany. This acquisition aimed to permit DePuy Synthes, to improve its comprehensive interbody implant portfolio that comprises expandable interbody devices, titanium integrated PEEK technology & 3D-printed cellular titanium, for both open spinal surgery & minimally invasive. Scope of the Study Market Segments covered in the Report: By Surgery • Minimally Invasive Spine Surgery • Open Spine Surgery By Type • Thoracolumbar Devices • Cervical Fixation Devices • Interbody Fusion Devices By End User • Hospitals • Specialty Clinics • Others By Geography • North America o US o Canada o Mexico o Rest of North America • Europe o Germany o UK o France o Russia o Spain o Italy o Rest of Europe • Asia Pacific o China o Japan o India o South Korea o Singapore o Malaysia o Rest of Asia Pacific • LAMEA o Brazil o Argentina o UAE o Saudi Arabia o South Africa o Nigeria o Rest of LAMEA Companies Profiled • Zimmer Biomet Holdings, Inc. • Johnson & Johnson • Stryker Corporation • B. Braun Melsungen AG • Medtronic PLC • Alphatec Holdings Inc. • Globus Medical, Inc. • NuVasive, Inc. • Orthofix Medical, Inc. • Exactech, Inc. Unique Offerings • Exhaustive coverage • Highest number of market tables and figures • Subscription based model available • Guaranteed best price • Assured post sales research support with 10% customization free Read the full report: https://www.reportlinker.com/p06283468/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________

Though the United States appears to be coming out of the worst of the pandemic, COVID-19 isn't going away any time soon. And there remains the continued risk of another surge as more states relax...

Here's how to know if you are at risk of Long COVID following an infection and specific lingering symptoms that you should discuss with your doctor.

COVID-19 is surging again nationwide, driven by even more contagious new variants. In five states, the virus has begun spreading exponentially in recent weeks. But health experts in those states have related insights about the latest virus variants and advice on staying safe that's useful no matter where you live. Read on to find out more—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1 Wyoming According to the New York Times' coronaviru

You may know that there are links between the foods and drinks you consume and different kinds of cancers.For instance, red meat has been linked with higher colorectal cancer risk, and alcoholic beverages have been connected to higher risk of breast cancer, while cauliflower could help lower your chance of getting liver cancer.Now, new research suggests that eating more fish is linked with a higher risk of melanoma.In the study, published earlier this month in the journal Cancer Causes&Control,

A pediatric critical care physician said she continues to see young patients being admitted to the hospital after they tried a dangerous stunt or challenge they saw on TikTok.

Story at a glance Poor diet can lead to a variety of health issues including high blood pressure, obesity, and certain cancers. Social determinants of health, including the high cost of healthy food, can hinder widespread efforts to improve Americans’ nutrition habits. New preliminary research from The American Society of Nutrition found the vast majority…

Panels of outside vaccine advisers to the CDC and FDA both voted unanimously this week to back the shots from Moderna as well as Pfizer and BioNTech.

Millions of U.S. children between the ages of 6 months and 4 years will soon be eligible for COVID-19 shots. FatCamera/E+ via Getty ImagesFor many parents of kids under age 5, a safe and effective COVID-19 vaccine could not come soon enough. A full year and a half after shots first became available for adults, their wait is nearly over. On June 17, 2022, the Food and Drug Administration authorized both the Pfizer-BioNTech and Moderna COVID-19 shots for the nearly 20 million U.S. children between

Following a sign-off from the country's top two health care agencies, children as young as 6 months old can now be vaccinated against Covid-19 — more than two years after adults were first able to get the shots. The U.S. Food and Drug Administration authorized the vaccines, which are made by Cambridge's Moderna Inc. (Nasdaq: MRNA) and New York-based Pfizer Inc. (NYSE: PFE), on Friday following a unanimous recommendation from its advisory committee. The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices met on Friday and Saturday and also endorsed the shots.

The number of people with medical cannabis licenses in the U.S. rose to 2.97 million in 2020 from 678,408 in 2016, according to a study of state data

Syndax Pharmaceuticals has toiled for years toward finding cancer therapies that can improve the lives of patients.

(Reuters) -The U.S. Food and Drug Administration on Friday authorized two COVID-19 vaccines for children under 5, opening the door to vaccinating millions of the country's youngest children once the Centers for Disease Control and Prevention agrees. The FDA authorized Pfizer-BioNTech's COVID-19 vaccine for children aged 6 months to 4 years and Moderna Inc's shot for those 6 months to 17 years. Pfizer's is already authorized for those over the age of 5.

Story at a glance Wildfires are among the most devastating natural disasters, due in part to their tendency to recur in specific geographic areas. Aggravated by climate change, wildfires have become more frequent in recent decades, taking a toll on vulnerable rural communities and first responders alike. But improving access to mental health care and…

Is Pfizer stock a buy after the FDA signed off on its Covid vaccine for babies and toddlers? Is PFE stock a buy right now?

Fayette County remains at both a high transmission level and high COVID-19 community level, according to the latest update from the federal health agency. Here’s where the rest of the state stands.

Witthaya Prasongsin via GettyOne common symptom that people with autism struggle with is the inability to interpret facial expressions. This can lead to difficulty in reading social cues in their personal lives, school, workplace, and even media like movies and TV shows. However, researchers at MIT have created an AI that helped shed light on why exactly this is.A paper published on Wednesday in The Journal of Neuroscience unveiled research that found that neurotypical adults (those not displayi

All children 6 months and older are now eligible to receive the COVID-19 vaccine, the U.S. Centers for Disease Control and Prevention announced Saturday.

Every 36 seconds, someone dies of heart disease in the U.S., accounting for one in every four deaths of all causes, according to the Centers for Disease Control (CDC). That's why it's so crucial to take care of your heart health by lowering your blood pressure, blood sugar, and cholesterol levels. Making changes to your diet can help you achieve these heart health benchmarks, lowering your risk of heart attack, stroke, aneurysm, and other acute threats. In particular, experts say one popular bev

The U.S. Food and Drug Administration has authorized use of the COVID-19 vaccines from Pfizer and BioNTech, and from Moderna, for kids between six months and five years of age. The FDA's decision follows a lengthy review process, and the dosage for children under five is greatly reduced relative to those for older children and adults. While Pfizer's vaccine was previously authorized in the U.S. for people five and up, Moderna's inoculation was limited to those aged 18 or above.

Infectious disease specialist Dr. Monica Gandhi says the challenges brought on by the Omicron variant highlight the need for new vaccines: ones that are longer-lasting, that can protect us against future variants, that stop transmission and offer protection against all symptoms, including mild ones.